NCT05835505 Detoxification of the Liver In PSC (Dolphin)
| NCT ID | NCT05835505 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Brigham and Women's Hospital |
| Condition | Primary Sclerosing Cholangitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 28 participants |
| Start Date | 2023-12-12 |
| Primary Completion | 2027-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 28 participants in total. It began in 2023-12-12 with a primary completion date of 2027-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a clinical trial being done to investigate the efficacy of drug BRS201 (hydroxocobalamin) as a treatment in patients with primary sclerosing cholangitis. Participation in this study will take 8 weeks long and the study is structured as a cross-over study in which participants will take the study drug for 4 weeks and a placebo drug for 4 weeks in a randomized order in the form of an oral medication. Participation may also involve receiving an IV dose of the medication. The study will require participants to attend 9 study visits, all of which will be remote. Participation will involve taking an oral medication twice daily, tracking the medication in a log, and getting blood drawn and giving a stool sample for a few lab tests throughout the study. For the lab tests, a research nurse will visit the participant in-home for the convenience of the participant.
Eligibility Criteria
Inclusion Criteria: * A diagnosis of PSC for at least 6 months based upon cholangiography (ERCP or MRCP) demonstrating intrahepatic and/or extrahepatic biliary strictures, beading or irregularity consistent with PSC. * ALP \> 1.5 times the upper limit of normal (ULN) at screening. * Subject must either be on a stable dose of ursodeoxycholic acid for \> 6 months prior to screening or have been discontinued \> 4 weeks prior to screening (enrollment of patients who are on UDCA will be limited to 60% of all enrolled patients). Exclusion Criteria: * Anticipated need for liver transplant within one year as determined by Mayo PSC risk score * Evidence of decompensated liver disease such as variceal bleeding, ascites, or hepatic encephalopathy. * Evidence of advanced liver disease including MELD score \> 10, bilirubin \> 3.0, platelet count \< 100,000; or INR \> 1.4 * Concomitant chronic liver disease including alcohol related liver disease, chronic hepatitis B or C infection, haemochromatosis, Wilson's disease, alpha1-antitrypsin deficiency, non-alcoholic steatohepatitis, autoimmune hepatitis, or primary biliary cholangitis * Secondary causes of sclerosing cholangitis * Patients who have a confirmed malignancy or cancer within 5 years except non-melanoma skin cancers * Treatment with any investigational agents, within two months or 5 half-lives of the investigational product, whichever is longer. * Active illicit drug or more than moderate alcohol consumption. * Evidence of bacterial cholangitis within 6 months of enrollment * In patients with Ulcerative Colitis, or, if Crohn's disease, a need for additional therapy at time of screening. * Chronic kidney injury (eGFR \< 60) * Pregnancy or lactation * Uncontrolled hypertension with a systolic BP \> 140 and a systolic BP \> 90 * Prohibited medications: current use of vitamin C and prednisone * Patients with a history or risk of cardiovascular conditions, including arrhythmia, long QT syndrome, congestive heart failure, stroke, or coronary artery disease * Patients with a history of kidney stones * Congenital or acquired immunodeficiencies * Other comorbidities including: diabetes mellitus, systemic lupus * An episode of acute cholangitis within 4 weeks of screening Check eligibility here: https://redcap.link/Checkmyeligibility
Contact & Investigator
Joshua A Korzenik, MD
PRINCIPAL INVESTIGATOR
Brigham and Womens Hospital
Frequently Asked Questions
Who can join the NCT05835505 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Primary Sclerosing Cholangitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05835505 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05835505 currently recruiting?
Yes, NCT05835505 is actively recruiting participants. Contact the research team at smitchell22@bwh.harvard.edu for enrollment information.
Where is the NCT05835505 trial being conducted?
This trial is being conducted at Chestnut Hill, United States.
Who is sponsoring the NCT05835505 clinical trial?
NCT05835505 is sponsored by Brigham and Women's Hospital. The principal investigator is Joshua A Korzenik, MD at Brigham and Womens Hospital. The trial plans to enroll 28 participants.